产品说明书

Lyn-IN-1

Print
Chemical Structure| 887650-05-7 同义名 : Bafetinib analog
CAS号 : 887650-05-7
货号 : A156158
分子式 : C30H31F3N8O
纯度 : 99%+
分子量 : 576.615
MDL号 : MFCD11973647
存储条件:

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 50 mg/mL(86.71 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Bcr-Abl fusion tyrosine kinase is formed because of a reciprocal chromosomal translocation between chromosomes 9 and 22, producing the Philadelphia chromosome. Bcr-Abl is expressed in chronic myeloid leukemia(CML) and a chronic of acute lymphocytic leukemia[2]. Lyn-IN-1, synonyms for Bafetinib(INNO-406), is a tyrosine kinase inhibitor that against wild-type Bcr-Abl in human erythroleukemia K562 cells and human embryonic kidney 293T cells with IC50 values of 11nM and 22nM, respectively. Lyn-IN-1 also suppresses the phosphorylation of platelet-derived growth factor receptor (PDGFR) and c-Kit. In vitro, Lyn-IN-1 effectively inhibited the kinase activity of both Tyr393-phosphorylated and Tyr393-unphosphorylated forms of Abl with respective IC50 values of 72nM and 30nM, suggesting that Lyn-IN-1 had sufficiently high affinity for Bcr-Abl to enable it to bind even to an unfavourable conformation of the kinase. Lyn-IN-1 also inhibited the phosphorylation of Bcr-Abl bearing M244V, G250E, Q252H, Y253F, E255K, E255V, F317L, M351T, E355G, E359V, H396P and F486S mutations with IC50 values ranging in 81-1400nM, but it did not inhibit the phosphorylation of the T315I mutation. Lyn-IN-1 inhibited proliferation of K562 and U937 cells with IC50 values of 11nM and 10μM, respectively[3]. Lyn-IN-1 inhibited proliferation of Human mast cell (HMC)-1 with IC50 value of 51nM. Lyn-IN-1 inhibited KIT phosphorylation and inducted apoptosis in HMC-1 cells[4]. In vivo, oral administration of Lyn-IN-1 at 0.2mg/kg twice daily for 10 days significantly inhibited tumor growth, while at 20mg/kg/day completely inhibited tumor growth without adverse effects in Balb/c-nu/nu mouse bearing xenografted KU812 cells. Oral administration of Lyn-IN-1 at 200mg/kg/day significantly prolonged the survival of the Balb/c-nu/nu mice intravenously injected with BaF3/wt cells. In addition, treatment of mice bearing BaF3 cells expressing Bcr-Abl bearing M244V, G250E, Q252H, Y253F, E255K, M351T or H396P mutations with Lyn-IN-1 at a dose of 20mg/kg/day showed significant prolongation of survival without any apparent signs of toxicity[3].
作用机制 The characteristic structural features of Lyn-IN-1 are a trifl uoromethyl group on the D ring that occupies a hydrophobic pocket of the Abl ligand-binding site and an adjacent dimethylaminopyrrolidine E ring whose rotation is restricted by the trifl uoromethyl group[3].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.73mL

0.35mL

0.17mL

8.67mL

1.73mL

0.87mL

17.34mL

3.47mL

1.73mL

参考文献

[1]WO2014169128A1

[2]Skorski T. BCR-ABL1 Kinase: Hunting an Elusive Target with New Weapons. Chemistry & Biology, 2011, 18(11): 1352-1353

[3]Niwa T, Asaki T, Kimura S, et al. NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor. Analytical chemistry insights, 2007, 2(1): 93-106

[4]Pan J , Alfonso Quintás-Cardama, Manshouri T , et al. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer science, 2007, 98(8):1223-1225